Research
Energy balance
Emerging therapies for genetic and syndromic obesities include approved treatments like setmelanotide and semaglutide.
Practitioners should consider the use of approved therapies like setmelanotide and semaglutide in treatment plans.
StrongSupportsmedium confidence
This review provides an overview of the current therapeutic landscape for genetic and syndromic obesities, including approved treatments such as setmelanotide and semaglutide, as well as emerging investigational drugs.
Why this rating
The abstract provides specific examples of approved treatments.
Source
From genes to care: the expanding therapeutic horizon in rare genetic obesities
Sarah Chalopin et al. · Obesity and Endocrinology · 2025
DOI 10.1093/obendo/wjaf007
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →